ISNES, Belgium, Aug. 9, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that the 3-year sample collection has been completed in the prospective study undertaken in collaboration with the University of Oxford, England to assess Volition's proprietary Nu.Q™ platform technology for the diagnosis of endometriosis through a simple blood test. Volition has now commenced running its discovery grade assays through the cohorts and expects to report preliminary data over the coming months.
Dr. Jake Micallef, Volition's Chief Scientific Officer, commented "Endometriosis is a potentially debilitating inflammatory condition in which the endometrial tissue that normally lines the inside of the uterus, grows outside the uterus, typically damaging the ovaries, fallopian tubes or other tissues of the pelvic cavity. Volition owns patents in the detection of endometriosis using nucleosome assays and we look forward to investigating the use of Nu.QTM technology in this large patient cohort."
Early detection and diagnosis of endometriosis remains one of the most important unaddressed medical needs in women's health. Endometriosis is the leading cause of female infertility, is extremely painful and affects huge numbers of women – up to 10% of women of reproductive age. Endometriosis is still currently diagnosed surgically by laparoscopy and the time from presentation to diagnosis is typically 8-10 years. Volition believes that the existing methodology for detection demonstrates a clear need for a reliable non-invasive diagnostic.
Collection of the samples was led by Professors Christian Becker and Krina Zondervan of the Nuffield Department of Women's and Reproductive Health, University of Oxford, who are also co-Directors of the Oxford Endometriosis Care and Research Centre (CaRe). Blood samples were collected prospectively from 350 patients over a period of more than 3 years following the Endometriosis Phenome and Biobanking Harmonisation Project (EPHect) guidelines supported by the World Endometriosis Research Foundation (WERF). Differences in circulating nucleosomes will be evaluated between women and across the menstrual cycle using Volition's Nu.QTM technology platform.
Professor Becker said: "We are looking forward to the results of this study which very much complements our ongoing efforts at the Oxford Endometriosis CaRe Centre of identifying non-invasive biomarkers for endometriosis which we believe will be an essential step towards improved patient diagnosis and care."
Cameron Reynolds, Chief Executive Officer of Volition, commented "We are delighted to be working with the Oxford Endometriosis CaRe Centre. We hope to build on our ongoing Nu.QTM work in cancer screening by exploring important disease applications beyond cancer to demonstrate the breadth of our Nu.QTM technology with our newly improved assays."
Volition is a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers. The tests are based on the technology platform of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.
As cancer screening programs become more widespread, Volition's products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.
Volition intends to expand the application of its technology beyond cancer by exploring other disease applications. The company's research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as it focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.
For more information about Volition, visit Volition's website https://volitionrx.com/
or connect with us via:
The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.
Louise Day, Chief Marketing & Communications Officer
+44 (0)7557 774620
Scott Powell, Executive Vice President, Investor Relations
+1 (646) 650 1351
Joseph Green, Edison Advisors
+1 (646) 653 7030
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of Volition's bodily-fluid-based diagnostic tests as well as Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and/or other disease applications. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if Volition fails to develop and commercialize diagnostic products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic products Volition might develop; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics®, NuQ®, Nu.QTM and Hypergenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.
SOURCE VolitionRx Ltd
Released August 9, 2018